{
  "id": 20286298,
  "title": "Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront",
  "url": "https://urgent.news/2026/11/16/johnson-johnson-agreed-to-buy-eye-disease-biotech-ollin-for-2-2",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-16T14:20:26.000Z",
  "source": {
    "name": "Quartz",
    "slug": "quartz",
    "url": "https://qz.com/johnson-johnson-ollin-biosciences-acquisition-eye-disease-111626"
  },
  "original_language": "en",
  "account": null,
  "summary": "Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}